Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.
Nivolumab/Ipilimumab Plus Chemotherapy as Frontline Therapy Shows Continued Efficacy in mNSCLC
June 5th 2023Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.
Read More
Following Prior Immunotherapy Resistance in Advanced PD-L1+ NSCLC Rilvegostomig Shows Promise
June 4th 2023Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512